Latest From Orphazyme AS
Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.
The latest submission and expedited review program news and highlights from our US FDA Performance Tracker.
Merrimack's wind-down continues with an activist challenge, but investors approved the Vical/Brickell Biotech reverse merger. Also, the past month's IPO slump may reverse course and HiFiBiO's $67m Series C leads recent financings.
Even with numerous endpoint misses, such is the demand for treatment options for the ultra-rare disease Niemann Pick, Orphazyme is pushing forward with its US and European regulatory filings of arimiclomol, which has no approved therapies in the US and one in the EU.
- Large Molecule
- Therapeutic Areas
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Orphazyme APS
- Western Europe
- Parent & Subsidiaries
- Orphazyme AS
- Senior Management
Anders Hinsby, PhD, CEO
Anders Vadsholt, CFO
Thomas Kirkegaard Jensen, PhD, CSO
Thomas Blaettler, MD, CMO
Paul Merrigan, Chief Commercial Officer
- Contact Info
Phone: 39 17 82 72
Ole Maaløes Vej 3
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.